Changes in methacholine induced bronchoconstriction with the long acting beta 2 agonist salmeterol in mild to moderate asthmatic patients.
about
Addition of long-acting beta2-agonists to inhaled corticosteroids versus same dose inhaled corticosteroids for chronic asthma in adults and childrenAddition of long-acting beta2-agonists to inhaled steroids versus higher dose inhaled steroids in adults and children with persistent asthmaAddition of inhaled long-acting beta2-agonists to inhaled steroids as first line therapy for persistent asthma in steroid-naive adults and childrenRegular treatment with salmeterol for chronic asthma: serious adverse eventsAddition of inhaled long-acting beta2-agonists to inhaled steroids as first line therapy for persistent asthma in steroid-naive adultsLong-acting beta2-agonists for chronic asthma in adults and children where background therapy contains varied or no inhaled corticosteroidLong-acting beta2-agonists for stable chronic asthmaSalmeterol tachyphylaxis in steroid treated asthmatic subjects.Asthma control during long-term treatment with regular inhaled salbutamol and salmeterol.Long-acting beta2-agonists: comparative pharmacology and clinical outcomes.Long-acting beta 2-agonists. Role in primary care asthma treatment.Salmeterol xinafoate in the treatment of mild to moderate asthma in primary care. UK Study GroupLong-acting inhaled beta agonists.Tolerance with beta 2-adrenoceptor agonists: time for reappraisal.Salmeterol: its place in asthma management.Functional antagonism: tolerance produced by inhaled beta 2 agonistsSalmeterol added to inhaled corticosteroid therapy is superior to doubling the dose of inhaled corticosteroids: a randomized clinical trial.
P2860
Q24235303-C2672CA7-A5B1-4DD9-B0F5-48555CFBEC4DQ24235964-DCEC3DFA-6C68-4ED7-8642-1410A102F74DQ24240464-DB339115-BFEF-41EE-8A9E-CEE430F22C9DQ24241960-E410934A-6033-49AB-B26F-D514358F9A61Q24245719-86A8060C-8E2D-448B-995E-ABE32768AEEAQ24246441-0F301EAE-05A7-4DF0-8E0B-3EA3972FB340Q24247926-41EE868F-2FC7-4BFE-9B34-2E505FD1AD23Q33775495-6ACC4CE3-D2FD-45EC-8754-BAE096A56C27Q35532670-460BCCA5-2BA8-4EE2-B209-47A61F7E634BQ35627925-5ACF3F37-2C0D-42B1-A6BE-C833DC48135CQ36479702-DC41CEEC-F5E7-47A8-876B-8EF69C5034E8Q36576295-F03CC540-FB2A-4FCE-B13A-D6D7AB158CDAQ40433878-3AB85A69-61FF-4540-BA0F-65CFDFFA2801Q40520444-D8B55E83-6CC2-4A4F-9F08-650DB0D7729AQ40558192-A2135287-0C19-4CA0-AF20-C7C240BF1A2AQ41207925-975AD7AA-D34F-4AB3-91CF-5739E42C155AQ48736327-010C6C33-443B-4AE0-A845-CA4C910A7099
P2860
Changes in methacholine induced bronchoconstriction with the long acting beta 2 agonist salmeterol in mild to moderate asthmatic patients.
description
1993 nî lūn-bûn
@nan
1993年の論文
@ja
1993年学术文章
@wuu
1993年学术文章
@zh-cn
1993年学术文章
@zh-hans
1993年学术文章
@zh-my
1993年学术文章
@zh-sg
1993年學術文章
@yue
1993年學術文章
@zh
1993年學術文章
@zh-hant
name
Changes in methacholine induce ...... o moderate asthmatic patients.
@ast
Changes in methacholine induce ...... o moderate asthmatic patients.
@en
type
label
Changes in methacholine induce ...... o moderate asthmatic patients.
@ast
Changes in methacholine induce ...... o moderate asthmatic patients.
@en
prefLabel
Changes in methacholine induce ...... o moderate asthmatic patients.
@ast
Changes in methacholine induce ...... o moderate asthmatic patients.
@en
P2093
P2860
P356
P1433
P1476
Changes in methacholine induce ...... o moderate asthmatic patients.
@en
P2093
P2860
P304
P356
10.1136/THX.48.11.1121
P407
P577
1993-11-01T00:00:00Z